Obstructive sleep apnea syndrome (OSAS) is a chronic condition characterized by recurrent episodes of partial or complete upper airway collapse during sleep. 1 OSAS presents with intermittent hypoxia, increased respiratory effort, sleep fragmentation, and disruptive snoring together with daytime somnolence. 1 Observational data showed that OSAS is associated with an increased risk of cardiovascular (CV) events. 2, 3 The increased incidence of cardiac arrhythmias (atrial fibrillation, ventricular arrhythmias, and sudden cardiac death) 4, 5 and heart failure 6 could help explain the high CV mortality associated with OSAS. Since all these complications are manifestations of atherosclerotic vascular disease, it was postulated that OSAS may promote atherosclerosis. 7 Therefore, it is relevant to investigate potential associations of OSAS with established vascular risk factors.
Hypertension is an established CV risk factor associated with the presence of OSAS. 8, 9 This association may be independent of the presence of obesity. 9 Treatments for OSAS may achieve small decreases in blood pressure (BP). 10 Intermittent hypoxia promotes persistent elevations of BP by enhancing sympathetic tone, while inducing oxidative stress, inflammation, and endothelial dysfunction. 11 The OSASrelated hypertension has a diastolic predominance and a nondipping pattern, 12, 13 while resistant hypertension is frequent due to increased levels of plasma aldosterone. 14 Of interest, it was suggested that OSAS and hypertension may have additive independent effects on atherosclerosis. 15 In this context, hypertension may not be the only CV risk factor associated with OSAS. 11 The predominance of small dense low-density lipoprotein (sdLDL) particles is considered a predictor of CV events. 16, 17 In this issue of Angiology, Sopkova et al report that the presence of metabolic syndrome (MetS), but not OSAS, independently predicted the small size of lowdensity lipoprotein particles in patients with OSAS. 18 MetS is a cluster of risk factors that include abdominal obesity, insulin resistance, elevated BP, and atherogenic dyslipidemia (levels of high triglycerides [TG] and low highdensity lipoprotein cholesterol [HDL-C]). 19 MetS is considered a proinflammatory and procoagulant state associated with increased sympathetic activity, endothelial dysfunction, and higher cholesterol concentration of the atherogenic sdLDL. 20,21 Thus, MetS promotes atherogenesis and increases the risk of CV events. 22 In the study by Sopkova et al, 18 among MetS components, levels of low HDL-C and high TG were the major independent determinants of sdLDL in patients with OSAS. This is in accordance with our previous findings that increased levels of TG and waist circumference comprise the main predictors of increased concentration of sdLDL in MetS. 20,23 This finding implies that increased atherogenesis in OSAS may, at least in part, be mediated by the presence of MetS.
All components of MetS, including hypertension, 24,25 insulin resistance, 26,27 and low HDL-C, together with high levels of TG 28,29 are frequent in patients with OSAS. 29 Furthermore, HDL may be dysfunctional in these patients. 30 Habitual snoring, as a surrogate marker of OSAS, was associated with the number of MetS components in a dose-dependent manner. 31 Therefore, it is not surprising that the prevalence of MetS is increased in patients with OSAS. 32, 33 In this context, OSAS was considered as a ''manifestation of MetS.'' 34 Also, the coexistence of these conditions has been termed as ''syndrome Z.'' 35 It is difficult to settle a causal relationship between MetS and OSAS since they share common predisposing factors. These factors include increased age, obesity, and unhealthy lifestyle (sedentary lifestyle, smoking, and excessive alcohol intake). 36, 37 Interestingly, it was suggested that the association of MetS, or its components, with OSAS may be independent of age, body mass index, smoking, and alcohol drinking. 32, 38 To this extent, intermittent hypoxia independently increases insulin resistance thereby adversely affecting glucose and lipid metabolism. 39, 40 Mechanisms to mediate these effects include oxidative stress, sympathetic activation, and inflammation. 41 Intermittent hypoxia induces dyslipidemia by upregulating lipid biosynthesis in the liver, by increasing adipose tissue lipolysis, and by inhibiting lipoprotein clearance. 28 These mechanisms resemble the pathogenic pathways of dyslipidemia associated with MetS.
Except for its components, MetS exhibits other atherogenic features in common with OSAS, for example, endothelial dysfunction. 42, 43 Endothelial dysfunction is the initial event that triggers inflammatory and thrombotic procedures during atherogenesis. 44 Intermittent hypoxia can induce endothelial dysfunction by decreasing nitric oxide availability, while increasing the levels of angiotensin II or endothelin-1. [45] [46] [47] Furthermore, it was suggested that OSAS is associated with increased endothelial cells apoptosis 43 and impaired vascular repairing process by endothelial progenitor cells. 48 Increased oxidative stress and inflammation in both OSAS and MetS also contribute to impaired endothelial function. 49 In obstructive sleep apnea, cycles of hypoxia/reoxygenation facilitate the formation of reactive oxygen species (ROS), which impair endothelial function 50 and promote lipid and glucose peroxidation. 51, 52 Peroxidation products may be associated with augmented atherosclerosis in OSAS even in the absence of obesity. 51 Furthermore, increased formation of ROS can activate inflammatory responses. 53 As with MetS, OSAS is associated with increased levels of C-reactive protein (CRP), which is a risk marker of CV disease. 54 It remains controversial whether the increased levels of CRP in OSAS are dependent on the presence of obesity. 53, 55 The levels of several proatherogenic inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a), are increased in patients with OSAS possibly independently of obesity. 53 Furthermore, OSAS was independently associated with increased circulating levels of inflammatory adhesion molecules, including intracellular adhesion molecule-1, vascular adhesion molecule-1, as well as L-selectin and E-selectin. [56] [57] [58] Inflammatory responses may also be mediated by several adipokines. For example, increased levels of leptin were noted in both patients with OSAS and MetS. 59, 60 Leptin increases the expression of inflammatory mediators, including IL-6 and TNF-a. 26 Of interest, levels of leptin are increased in OSAS independently of obesity. 59 Data are inconclusive for the effect of OSAS on the circulating levels of other adipokines including adiponectin and visfatin. 53 Increased platelet activation and aggregation are the other common features of MetS and OSAS. 61, 62 The OSAS (in parallel with the severity of the disease) is associated with increased mean platelet volume (MPV) and platelet distribution width, which are surrogate markers of platelet activation. 63 The MPV is related to the prognosis of CV disease. 64 This disorder can be improved by the treatment of OSAS. 65 It was suggested that platelet activation in OSAS is related to sympathetic nervous system overactivity, 66 hypoxia, 67 and chronic inflammation. 68 Furthermore, an increased expression of platelet-derived microparticles adversely affecting coagulation and fibrinolysis, including soluble fibrin and plasminogen activator inhibitor-1, was noted in patients with OSAS. 69 Also, OSAS-related hypercoagulable state could be associated with increased plasma levels of fibrinogen and factor VII. 70 Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with either OSAS or MetS. 71, 72 Obesity, dyslipidemia, and increased insulin resistance contribute to the development of NAFLD in both the conditions. 71 Other mechanisms that apply to both OSAS and MetS include increased oxidative stress and inflammation in the liver. 71 Of interest, in patients with OSAS markers of hypoxia were better predictors of serum aminotransferase activities than factors related to MetS. 73 Furthermore, it was suggested that OSAS can accelerate the progression of NAFLD to nonalcoholic steatohepatitis. 71 Nonalcoholic fatty liver disease is an emerging risk factor for CV disease. 74 In this context, it was suggested that the liver enzyme activities can well predict CV morbidity and mortality. 75 An increased activity of g-glutamyltransferase (gGT) was noted in patients with OSAS in parallel with the severity of the disease. 76 Of interest, gGT was an independent predictor of CV disease in these patients. 76 Elevated levels of serum uric acid (SUA) may be associated with increased CV morbidity and mortality. 74, 77 Hyperuricemia is common in patients with MetS. 78 Furthermore, intermittent hypoxia may increase levels of SUA. 79 In this context, levels of SUA are commonly elevated in patients with OSAS depending on the severity of the disease. 80, 81 Of interest, it was suggested that overnight increase in urinary excretion of uric acid could serve as a marker of tissue hypoxia in patients with OSAS. 82 However, it is inconclusive whether this association is independent of the presence of obesity. 80, 83 Treatment of OSAS can significantly decrease levels of SUA. 84 In conclusion, both OSAS and MetS are associated with increased CV risk. Since these conditions share common predisposing factors, mostly obesity, their coexistence is common. Therefore, it is difficult to apportion the individual contribution of MetS, OSAS, or obesity to CV risk. Metabolic disorders and atherogenic pathways relating to CV risk are similar in OSAS and MetS. In this context, hypoxia may be associated with the presence of CV risk predictors in patients with OSAS even in the absence of obesity. On the other hand, it was suggested that several atherogenic features of OSAS may be entirely explained by the presence of MetS. In any case, it is important for clinicians to identify all atherogenic features of MetS in patients with OSAS. Correction of hypoxia can be useful in the management of these factors. Furthermore, the aggressive treatment of all MetS-related factors contributing to atherosclerosis could be effective in reducing CV risk in patients with OSAS.
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